Product label
What is it for?
The current label gives approved uses, forms, warnings, common reactions, and the checks tied to that product.
Source notes
See how the facts were checked
This page lists the official places the guide’s facts came from, so you can check them yourself. You do not need to read them to use the guide. The most useful single document is the label for your exact product: the official leaflet approved with the medicine, posted free on a government website called DailyMed.
Reading order
Use the source that can answer the question
Government record
What is its status?
The FDA keeps an online list of approved medicines, called Drugs@FDA, and a separate list of medicines in short supply. Your state’s medical board and pharmacy board keep the licence records for prescribers and pharmacies.
Journal paper
What happened in a trial?
A published study report shows who was studied, what the medicine was compared with, how long it ran, and what changed. This guide has already read these for you; the links are there if you want the original.
Checked on one date
What the federal records said in late September
Semaglutide and tirzepatide
As of September 26, 2026, semaglutide injections and tirzepatide were not on the FDA shortage list.
No FDA-approved generic of semaglutide (Ozempic or Wegovy) or tirzepatide (Mounjaro or Zepbound) could be marketed in the United States on that date.
Liraglutide
As of September 26, 2026, FDA-approved generic liraglutide existed for diabetes and weight uses.
Liraglutide injection was still on the FDA shortage list on that date.
No compounded medicine carries FDA approval, as of September 2026. FDA does not review its quality, safety, or effectiveness before it reaches the market.
Where to look